NR546 PSYCHOPHARMACOLOGY PMHNP MIDTERM EXAM
2026/2027 | Questions and Verified Answers |
Psychiatric-Mental Health Nurse Practitioner | Pass
Guaranteed - A+ Graded
Part I: Basic Principles of Psychopharmacology (PK/PD,
Neurobiology)
Q1: A 45-year-old patient with depression is prescribed a medication metabolized by
CYP2D6. Genetic testing reveals they are a poor metabolizer. What clinical implication
should the PMHNP anticipate?
A. The patient will require higher doses to achieve therapeutic effects
B. Drug levels will likely be elevated, increasing adverse effect risk [CORRECT]
C. The medication will be rapidly cleared, requiring more frequent dosing
D. CYP2D6 poor metabolizers are not clinically significant for psychotropic dosing
Correct Answer: B
,Rationale: Poor metabolizers have reduced or absent CYP2D6 enzyme activity, leading
to slower drug metabolism, higher plasma concentrations, and increased risk of adverse
effects. Option A describes ultrarapid metabolizers. Option C describes rapid clearance
seen in extensive metabolizers or with inducers. Option D is incorrect as CYP2D6
polymorphisms significantly impact drug metabolism and dosing.
Q2: Which neurotransmitter receptor antagonism is primarily responsible for the weight
gain and metabolic side effects commonly seen with second-generation
antipsychotics?
A. Dopamine D2 receptor antagonism
B. Serotonin 5-HT2A receptor antagonism
C. Histamine H1 receptor antagonism [CORRECT]
D. Muscarinic acetylcholine receptor antagonism
Correct Answer: C
Rationale: H1 histamine receptor antagonism drives appetite stimulation, weight gain,
and sedation. While 5-HT2A antagonism contributes to metabolic effects, H1 blockade
is the primary mediator of weight gain. D2 antagonism causes EPS and prolactin
elevation. Muscarinic antagonism causes anticholinergic side effects.
,Q3: A patient asks why their new antidepressant takes 4-6 weeks to work when they felt
sedated immediately. The PMHNP explains that immediate sedation reflects
antihistaminic effects, while antidepressant effects require:
A. Immediate receptor downregulation and enhanced neurotransmission
B. Gradual adaptive neuroplastic changes and receptor sensitization [CORRECT]
C. Accumulation of the drug to steady-state concentrations only
D. Complete elimination of the previous antidepressant from their system
Correct Answer: B
Rationale: Antidepressant efficacy involves delayed neuroplastic changes, including
downregulation of presynaptic autoreceptors, enhanced neurotrophic factor signaling,
and adaptive changes in postsynaptic receptor sensitivity—not just steady-state
pharmacokinetics. While steady-state is needed (option C), the therapeutic lag reflects
neuroadaptive processes.
Q4: Regarding pharmacokinetics, which factor most accurately describes why lipophilic
psychotropic medications like antipsychotics have long half-lives?
A. They undergo extensive first-pass hepatic metabolism
, B. They have large volumes of distribution and redistribute from adipose tissue
[CORRECT]
C. They are primarily eliminated unchanged by the kidneys
D. They strongly inhibit their own metabolic enzymes
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue (high Vd), creating
a reservoir that slowly releases drug back into circulation. First-pass metabolism (A)
affects bioavailability, not half-life. Renal elimination (C) applies to hydrophilic drugs.
Auto-inhibition (D) is not a typical pharmacokinetic principle.
Q5: A patient on carbamazepine for bipolar disorder notices their mood stabilizer seems
less effective after 3 weeks. The PMHNP recognizes this as likely due to:
A. Development of pharmacodynamic tolerance at receptor sites
B. Autoinduction of CYP3A4 increasing drug metabolism [CORRECT]
C. Downregulation of GABA receptors over time
D. Accumulation of toxic metabolites blocking therapeutic effects
2026/2027 | Questions and Verified Answers |
Psychiatric-Mental Health Nurse Practitioner | Pass
Guaranteed - A+ Graded
Part I: Basic Principles of Psychopharmacology (PK/PD,
Neurobiology)
Q1: A 45-year-old patient with depression is prescribed a medication metabolized by
CYP2D6. Genetic testing reveals they are a poor metabolizer. What clinical implication
should the PMHNP anticipate?
A. The patient will require higher doses to achieve therapeutic effects
B. Drug levels will likely be elevated, increasing adverse effect risk [CORRECT]
C. The medication will be rapidly cleared, requiring more frequent dosing
D. CYP2D6 poor metabolizers are not clinically significant for psychotropic dosing
Correct Answer: B
,Rationale: Poor metabolizers have reduced or absent CYP2D6 enzyme activity, leading
to slower drug metabolism, higher plasma concentrations, and increased risk of adverse
effects. Option A describes ultrarapid metabolizers. Option C describes rapid clearance
seen in extensive metabolizers or with inducers. Option D is incorrect as CYP2D6
polymorphisms significantly impact drug metabolism and dosing.
Q2: Which neurotransmitter receptor antagonism is primarily responsible for the weight
gain and metabolic side effects commonly seen with second-generation
antipsychotics?
A. Dopamine D2 receptor antagonism
B. Serotonin 5-HT2A receptor antagonism
C. Histamine H1 receptor antagonism [CORRECT]
D. Muscarinic acetylcholine receptor antagonism
Correct Answer: C
Rationale: H1 histamine receptor antagonism drives appetite stimulation, weight gain,
and sedation. While 5-HT2A antagonism contributes to metabolic effects, H1 blockade
is the primary mediator of weight gain. D2 antagonism causes EPS and prolactin
elevation. Muscarinic antagonism causes anticholinergic side effects.
,Q3: A patient asks why their new antidepressant takes 4-6 weeks to work when they felt
sedated immediately. The PMHNP explains that immediate sedation reflects
antihistaminic effects, while antidepressant effects require:
A. Immediate receptor downregulation and enhanced neurotransmission
B. Gradual adaptive neuroplastic changes and receptor sensitization [CORRECT]
C. Accumulation of the drug to steady-state concentrations only
D. Complete elimination of the previous antidepressant from their system
Correct Answer: B
Rationale: Antidepressant efficacy involves delayed neuroplastic changes, including
downregulation of presynaptic autoreceptors, enhanced neurotrophic factor signaling,
and adaptive changes in postsynaptic receptor sensitivity—not just steady-state
pharmacokinetics. While steady-state is needed (option C), the therapeutic lag reflects
neuroadaptive processes.
Q4: Regarding pharmacokinetics, which factor most accurately describes why lipophilic
psychotropic medications like antipsychotics have long half-lives?
A. They undergo extensive first-pass hepatic metabolism
, B. They have large volumes of distribution and redistribute from adipose tissue
[CORRECT]
C. They are primarily eliminated unchanged by the kidneys
D. They strongly inhibit their own metabolic enzymes
Correct Answer: B
Rationale: Lipophilic drugs distribute extensively into adipose tissue (high Vd), creating
a reservoir that slowly releases drug back into circulation. First-pass metabolism (A)
affects bioavailability, not half-life. Renal elimination (C) applies to hydrophilic drugs.
Auto-inhibition (D) is not a typical pharmacokinetic principle.
Q5: A patient on carbamazepine for bipolar disorder notices their mood stabilizer seems
less effective after 3 weeks. The PMHNP recognizes this as likely due to:
A. Development of pharmacodynamic tolerance at receptor sites
B. Autoinduction of CYP3A4 increasing drug metabolism [CORRECT]
C. Downregulation of GABA receptors over time
D. Accumulation of toxic metabolites blocking therapeutic effects
